Calcium Antagonists: Pharmacologic Agents in Search of New Clinical Indications
Author:
- 1 January 1990
- journal article
- review article
- Published by SAGE Publications in Angiology
- Vol. 41 (1) , 36-43
Abstract
The broad availability of new pharmacologic agents is usually followed by both the search for similar compounds with more specific and refined actions and the expansion of clinical applicability for these agents. During the last twenty years extensive investigations have revealed that calcium (Ca) antagonists hold a multifaceted pharmacodynamic potential that includes not only the antiarrhythmic and antihypertensive effects of the drug but also the protection against excessive Ca entry into the cells of the cardiovascular system and subsequent cell damage. The physiologic age-dependent Ca accumulation in the arterial wall, which inevitably appears after the second decade, reaches maximal values in the age group of eighty-one to ninety years when the aortic wall exhibits a total Ca content that is 100 times higher than in arteries of infants. In animals we also find age-dependent accumulation of Ca in the arterial wall that is severely aggravated by uncontrolled diabetes or hypertension. Fleckenstein has shown that this arterial calcinosis can be prevented by chronic administration of Ca antagonists. Furthermore, Fleckenstein has demonstrated that excessive Ca overload of myocardial tissue constitutes a basic pathologic process in the development of cardiac necroses—brought about by extreme beta-adrenergic drive (overdoses of catecholamines), high doses of vitamin D 3 , dihydrotachysterol, alimentary factors such as K or Mg deficiency, or genetic defects (hereditary cardiomyopathy). Even cardiac hypertrophy, either idiopathic or as a consequence of hypertension, can be prevented by the action of Ca antagonists. In addition, the uncontrolled Ca entry into the cell constitutes an important etiologic factor in microstructural impairment of the myocytes due to ischemia—hence Ca antagonists are successfully used as cardio-protective agents in cardioplegic solutions. More recently the tissue-protection action of Ca antagonists has also been proven to be effective in renal transplantation and inhibition of toxic liver injury. It can be concluded that Ca antagonists have an antiatherosclerotic, anticalcinotic, and tissue-protective potential that opens a wide spectrum of applications both prophylactic and therapeutic, especially in the cardiovascular field.Keywords
This publication has 35 references indexed in Scilit:
- The Interdependence of Hypertension, Calcium Overload, and Coronary Spasm in the Development of Myocardial InfarctionAngiology, 1988
- Protection of Arterial and Arteriolar Wall Structure by Specific Calcium AntagonistsAnnals of the New York Academy of Sciences, 1988
- Future directions in the use of calcium antagonistsThe American Journal of Cardiology, 1987
- Antiatherogenic properties of calcium antagonistsThe American Journal of Cardiology, 1987
- Experimental basis of the long-term therapy of arterial hypertension with calcium antagonistsThe American Journal of Cardiology, 1985
- Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheromasZeitschrift für Die Gesamte Experimentelle Medizin, 1985
- Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells. A possible mechanism for its antiatherogenic effect.Journal of Clinical Investigation, 1985
- Mechanism of protection from atherosclerosis by verapamil in the cholesterol-fed rabbitThe American Journal of Cardiology, 1984
- The effect of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosisAtherosclerosis, 1975
- Verapamil in the treatment of paroxysmal supraventricular tachycardiaPostgraduate Medical Journal, 1974